Literature DB >> 17559840

Inhibitors of the heat shock response: biology and pharmacology.

Marissa V Powers1, Paul Workman.   

Abstract

A number of human diseases can be linked to aberrations in protein folding which cause an imbalance in protein homeostasis. Molecular chaperones, including heat shock proteins, act to assist protein folding, stability and activity in the cell. Attention has begun to focus on modulating the expression and/or activity of this group of proteins for the treatment of a wide variety of human diseases. This review will describe the progress made to date in developing pharmacological modulators of the heat shock response, including both agents which affect the entire heat shock response and those that specifically target the HSP70 and HSP90 chaperone families.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17559840     DOI: 10.1016/j.febslet.2007.05.040

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  128 in total

1.  HSP70 inhibition by the small-molecule 2-phenylethynesulfonamide impairs protein clearance pathways in tumor cells.

Authors:  J I-Ju Leu; Julia Pimkina; Pooja Pandey; Maureen E Murphy; Donna L George
Journal:  Mol Cancer Res       Date:  2011-06-02       Impact factor: 5.852

Review 2.  Protein folding in the cytoplasm and the heat shock response.

Authors:  R Martin Vabulas; Swasti Raychaudhuri; Manajit Hayer-Hartl; F Ulrich Hartl
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-12       Impact factor: 10.005

3.  Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines.

Authors:  Young-Mee Kim; Hongryull Pyo
Journal:  DNA Cell Biol       Date:  2011-08-10       Impact factor: 3.311

Review 4.  Heat shock protein 70 (hsp70) as an emerging drug target.

Authors:  Christopher G Evans; Lyra Chang; Jason E Gestwicki
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

5.  Integration-mediated prediction enrichment of quantitative model for Hsp90 inhibitors as anti-cancer agents: 3D-QSAR study.

Authors:  Kuldeep K Roy; Supriya Singh; Anil K Saxena
Journal:  Mol Divers       Date:  2010-08-26       Impact factor: 2.943

Review 6.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

7.  Inhibition of heat shock induction of heat shock protein 70 and enhancement of heat shock protein 27 phosphorylation by quercetin derivatives.

Authors:  Rongsheng E Wang; Jeffrey L-F Kao; Carolyn A Hilliard; Raj K Pandita; Joseph L Roti Roti; Clayton R Hunt; John-Stephen Taylor
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

8.  Luteal serum BDNF and HSP70 levels in women with premenstrual dysphoric disorder.

Authors:  E Oral; H Ozcan; T S Kirkan; S Askin; M Gulec; N Aydin
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-03-02       Impact factor: 5.270

9.  Cisplatin abrogates the geldanamycin-induced heat shock response.

Authors:  Andrea K McCollum; Kara B Lukasiewicz; Cynthia J Teneyck; Wilma L Lingle; David O Toft; Charles Erlichman
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

10.  Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis.

Authors:  Qingqing Mo; Yu Zhang; Xin Jin; Yue Gao; Yuan Wu; Xing Hao; Qinglei Gao; Pingbo Chen
Journal:  Tumour Biol       Date:  2016-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.